The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This was an excellent interview posted on YouTube - missed this today as been away from screen for first time in over a month! I am sure all of this has been discussed today but "strong data sets catching the eyes of those people that matter" Need he say anymore. Hints at fundraising of course.
https://www.youtube.com/watch?v=uvHGsl4KfJE&feature=youtu.be
PS I work in a UK Russell Group University - I will let you know how it pans out first hand in a few weeks when our undergraduates return... I am not confident at all. There is every reasonable bubble/covid-secure etc measure in place but you can't stop them mixing and this is a generation with let's say diminished respect for an older generation holding all the cards.
Viral load is the big unknown and I am not sure beyond qualitative assessments whether this has been measured yet? or how?
But it makes sense as an individual to reduce that risk. You may catch a glancing blow from the virus but sitting in a room sucking it in for an hour might be much worse. I am not an immunologist but this effect must have been studied before with other viral infections?
He probably owns MF.
Only a few people reported so far remember - don't get beguiled by man bites dog stories. I would be surprised if this was NOT the case given the number of infections in total we are talking about.
Good spot!
I just wanted to say I am not sure what the obsession with peer review is on this board in terms of next steps. There have been several publicly funded health studies published around IFN-1b which many of us have posted - that is normal and has steadily built confidence - not to mention going back to SARS-COV in 2000s and evidence there that IFN-1b and corticosteroids were effective! But a company is under no obligation to publish in the public domain and as a few have stated, they will share their data with Pharma who will provide the necessary critique - not some selected reviewers from a journal who may or may not have competitive interests. Why would they waste their time with a paper that incidentally makes publishers a lot of cash for copy they pay nothing for but charge lavish subscriptions for. I hope they are focusing on the task in hand not public domain publication.
Yes, Motley-Fool Rachael FitzGerald-Finch produces another recycled blurb. I swear they are bots.
Woodstock - very sobering posts. I think i saw written somewhere that The West had enjoyed essentially escapism or break from history for about 50 years - up until 11/09/2001 that is.
Back on topic. Here is a study published in August- South Korean study, five patients and triple therapy including IFN-1b. Best figure 1 ever, with pictures of ambulance, hospital and then a smiley face to mark recovery - you can scan the info in a few seconds. All five severely ill patents got smiley faces. I am trying to keep track to make sure I don't duplicate any posts. Only posting publications that appear in August on Web of Science using search of COVD-19 and Interferon but this may have been highlighted in pre-print by others.
https://www-sciencedirect-com.bris.idm.oclc.org/science/article/pii/S0924857920302223?via%3Dihub
Yes, I am sure along with most still on here we were expecting/hoping for something around treatments/progress etc. But car tyres it is. Okay, slightly bemused and time for bed.
OMG - WTF is this man blithering about - he is all over the place. He is outdoing himself, yet again.
Yep still waiting for the stream
No it isn't, but pockets of it are going to be hit hard. 2020 is a wake up call. Remember we receive two freebies every single day - sunshine (a net influx of free energy) and time- both of which give us the capacity to create for free. That is what sustains everything, there is nothing else. As long as we don't rush and screw things up the world is literally our oyster, we have all the time the world to do stuff. Go too fast and we screw it up. My personal feeling is we have hurtled way too fast over the last 50 years and are paying the price across numerous fronts. We just need to slow down.
Maybe Airferon
This was S.C. administration
Hi All - I try to keep track of which preprints I have posted or published works but I have not posted this one. It was received back in April and now published and reviewed (i.e. timescales...). may have been posted before but not by me. Non-Controlled trial, combination, including IFN-b1a. 20 hospitalised patients, all recovered.
'We had three main limitations in this study including lack of the
control group, confounding effects of concurrent medications, and
small sample size. Also, the ethical challenges push us not to consider
the control group who were deprived of effective treatment. In this
study, all patients received the combination of IFN-ß-1a, hydroxychloroquine,
and lopinavir/ritonavir according to the national Iranian guideline on COVID-19 treatment and we could not administer solely
IFN-ß-1a [22]. Hence, the net therapeutic effect of IFN-ß-1a along with
all other drugs may not be established exactly. With considering the
mentioned limitations, the results of this study should be interpreted
cautiously and further large trials are needed to show the therapeutic
effects of IFN-ß-1a in COVID-19. Also, we suggest future trials to consider
the therapeutic effects of other types of IFN including IFN-a in
COVID-19. Our findings support the use of IFN-ß-1a in combination
with hydroxychloroquine and lopinavir/ritonavir in the management of
COVID-19.'
Taken in isolation the above is true but the picture is building IMHO.... likely that hydroxychloroquine and lopinavir/ritonavir were not contributing a whole lot here but synergistic (additive) effects really haven't been properly tested at all.
I second that...
Hi - The name Rebif is short for recombinant beta interferon, I.e. protein produced by expression of the gene in a foreign host, eg E. coli. That way you can prepare a lot of it through culturing, much more than extracting directly from the real host, not viable! So it is just the generic name for the protein. After that it is all about how it is formulated.
What I have not looked into is the detail of the formulation used in SNG-001. The paper from the 80s posted yesterday referred to irritation of nasal passages when early formulations of IFN were used. So a key part of SNG-001 might be how they have made a neutral pH, additive formulation that keeps IFN active, I.e. natively folded so it works. Perhaps that is not as easy as it looks but I have not honestly checked. It was good to see their formulation is stable for many months....
Thanks LordGibil, a good reminder of how long this concept has been around!
Hi All, I have published over 100 papers and have plenty of experience of the normal review process which is write up results as a paper, submit to suitable journal, suggest reviewers, some of whom maybe chosen but also other anonymous reviewers as well are selected. Then wait (I review too, we are all busy and can take up to a month or more). Studies are usually criticised on technical points and impact.
So SNG team released results as they were obliged to do but who knows how long it took them to write the study up for publication or when they submitted it. I presume that was happening once trial was uncovered. Review process in many journals has been expedited with reviewers asked to review in a few days for Covid research. We have already seen the top line criticisms of statistical significance but review may ask the team to adjust their claims if they feel there are other technical issues.
We have seen posts by fellow academics but they have. It had the complete datasets. As someone said, pharma will have seen the data in their presumed discussions and arguably will form their own decisions. Also many academics who would be likely reviewers probably serve as advisers on scientific boards at these companies anyway.